ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 189

Nutraceutical Therapy with Polyphenol-Rich Pomegranate Fruit Extract (POMx) Inhibits Systemic NFκB-Mediated Inflammation in a Murine Model of Endotoxemia

Nicholas A. Young1, Misha Mobeen2, Tariq M Haqqi3 and Wael N. Jarjour4, 1Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, 2The Ohio State University Wexner Medical Center, Columbus, OH, 3Anatomy & Neurobiology, Northeast Ohio Medical University, Rootstown, OH, 4Department of Rheumatology/Medicine, Ohio State University, Columbus, OH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Inflammation, innate immunity and therapy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Innate Immunity and Rheumatic Disease - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  The pomegranate fruit is cultivated worldwide for dietary consumption, but has been used therapeutically in Eastern medicine from times dating back to ancient Egypt due to its potent anti-inflammatory properties. Recent studies have attributed this well-documented immunomodulatory influence to anthocyanin and hydrolysable tannins, which are polyphenolic compounds contained in the edible part of the fruit. A commercially- standardized nutraceutical preparation of a polyphenol-rich pomegranate extract (POMx) has previously been created and shown to suppress disease activity in a murine model of rheumatoid arthritis and inhibit NFkB activity in human cell lines. In the present study, our objective was to establish an animal model to longitudinally measure systemic effects of POMx on NFkB-mediated inflammation in vivo.

Methods:  Endotoxemia was induced in BALB/C-Tg(NFkB-RE-luc)-Xen mice, which have a firefly luciferase cDNA reporter gene under the regulation of 3 kB responsive binding sites, by injection of lipopolysaccharide (LPS). NFkB-mediated inflammation was determined following a sub-lethal dose of LPS (2 mg/kg) by measuring whole-body bioluminescent signals using the Xenogen in vivo imaging system (IVIS 200). The emitted photons were quantified for each mouse at baseline, 2 hr, 4 hr, and 24 hr. Lethal endotoxemia was induced by LPS injection (25 mg/kg) for survival curve analysis. Prior to any LPS injection, mice were pre-treated for one week with water or POMx (34mg/kg/day) and continued daily treatment was provided in survival experiments.

Results:  Relative to NFkB-RE-luc mice given water, POMx inhibited NFκB-induced luciferase activity after sub-lethal endotoxemia induction with LPS injection. Systemic inflammatory responses measured by IVIS photon quantification of NF-kB activation were significantly suppressed with POMx treatment. Lethal endotoxemia led to 50% survival of control mice receiving water after 24 hr, but POMx treatment resulted in 100% survival. Subsequently, while all controls did not survive past 48 hr, daily dosing of POMx resulted in 20% total survival after 7 days.

Conclusion:  This novel application of the NF-kB-regulated luciferase mouse model establishes a system that may facilitate the future therapeutic development of POMx as an anti-inflammatory nutraceutical extract by enabling the longitudinal analysis of systemic NFkB-mediated inflammatory responses and will permit further elucidation of the mechanism of NFkB inhibition in vivo.  


Disclosure: N. A. Young, None; M. Mobeen, None; T. M. Haqqi, None; W. N. Jarjour, None.

To cite this abstract in AMA style:

Young NA, Mobeen M, Haqqi TM, Jarjour WN. Nutraceutical Therapy with Polyphenol-Rich Pomegranate Fruit Extract (POMx) Inhibits Systemic NFκB-Mediated Inflammation in a Murine Model of Endotoxemia [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/nutraceutical-therapy-with-polyphenol-rich-pomegranate-fruit-extract-pomx-inhibits-systemic-nf%ce%bab-mediated-inflammation-in-a-murine-model-of-endotoxemia/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nutraceutical-therapy-with-polyphenol-rich-pomegranate-fruit-extract-pomx-inhibits-systemic-nf%ce%bab-mediated-inflammation-in-a-murine-model-of-endotoxemia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology